Effectiveness and Safety of Tofacitinib in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA) That Affects the Whole Body
Efficacy, Safety, Tolerability and Pharmacokinetics of Tofacitinib for Treatment of Systemic Juvenile Idiopathic Arthritis (sJIA) With Active Systemic Features in Children and Adolescent Subjects
Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT03000439
Protocol ID: A3921165
PrintDownloadOpen Plain Language Summary Result: Click here